The Pharma Data

JANUARY 31, 2021

Ralf Clemens , Chairman of the Scientific Advisory Board for Clover’s COVID-19 Vaccine Program said, “This phase 1 dose-finding and adjuvant justification study demonstrated the potential of Clover’s adjuvanted vaccine candidates to bring added value to the global portfolio of COVID-19 vaccines. About Trimer-Tag© Technology.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

XTalks

DECEMBER 13, 2023

Related: Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod Casgevy and Lyfgenia Pricing and Warnings The price tags of both gene therapies are steep, given the complexity of developing gene therapies and as therapies meant to be one-time treatments. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

OCTOBER 12, 2022

Perfusion imaging done by MRI has been used to assess the intrinsic microvascular properties of tumors before, during and after treatment with anti-angiogenic and vascular-targeting agents. For ASL MR perfusion, water molecules in arterial blood from a feeder artery are magnetically tagged and tracked until they reach the region of interest.

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. About Trimer-Tag © Technology. About COVID-19 S-Trimer Vaccine. S-Trimer is intended to be adjuvanted.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

pharmaphorum

JUNE 8, 2021

Dementia specialist Prof Robert Howard of University College London (UCL) was also damning in his assessment of the decision, saying that the FDA has “sidestepped available clinical trial outcomes data that indicate the drug probably doesn’t work.”

Drugs 98

Drugs Marketing FDA Approval Trials 98

Intouch Solutions

APRIL 11, 2024

This process is relatively straightforward when high-value medical-scientific content is readily available. Pre-Clinical : Deeper comprehension of the impacts and outcomes associated with a particular drug. Therefore, the initial but crucial step in engaging physicians is getting their attention.

Compliance 52

Compliance Marketing Drugs Pharma Companies 52

pharmaphorum

NOVEMBER 16, 2022

Yet, in the space of a decade, certain treatments have come along that have raised important questions over the future of treatment, reimbursement, and the value of the quality of life for patients. However, with a price tag of €1.58 How to navigate the new climate. At more than $2.1

Gene Therapy 131

Gene Therapy Gene Marketing Development 131

Pharmaceutical Technology

OCTOBER 10, 2022

Using sophisticated assignment rules and virtual tagging, each line item inside the unified bill can be assigned to its business role, feature, team, and product. The leadership team can use FinOps dashboards to track consumption and gross margin, assess unit cost over time, and then distribute it to clients.

Production 130

Production Engineer Development Marketing 130

Pharmaceutical Technology

JANUARY 27, 2023

On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based agreements in a slightly different way. However, Andrew Cournoyer, Senior Vice President of PRECISIONvalue, said this may make the process slightly more arduous for patients and physicians. “To

Manufacturing 130

Manufacturing Drugs Research Analyst FDA Approval 130

pharmaphorum

FEBRUARY 16, 2021

NICE is assessing Zynteglo (betibeglogene autotemcel), a one-off gene therapy for the condition, which can have life-threatening consequences and is associated with a curtailed life expectancy. million in Europe. NICE said that data came from a small sample of patients and is using its standard discount rate of 3.5%

Gene Therapy 93

Gene Therapy Gene Medicine Development 93

XTalks

SEPTEMBER 27, 2022

The record-breaking price tag of Skysona is not surprising for one-time gene therapies like it. The price tag reflects “the clinical benefit [it] provides as an urgently needed treatment option to slow the progression of neurologic dysfunction in children impacted by progressive, irreversible and fatal rare disease,” Obenshain added.

FDA Approval 52

FDA Approval Gene Therapy Drugs Gene 52